Bromo-DragonFLY

• (R) -1 - (4- Bromfuro [2,3- f] benzofuran- 8-yl ) propan- 2-amine (IUPAC preferred)
• (R )-8 -bromo- α -methyl -benzo [ 1,2-b :4,5 -b ' ] difuran -4- ethanamine
• DOB Dragonfly

• 502759-67-3

Crystalline solid (hydrochloride)

Agonist of 5- HT2A serotonin receptor

• DMSO in 5 mg / ml
• In DMF 1 mg / ml

Template: Infobox chemical / molecular formula search available

Bromo - Dragonfly is a research chemical with hallucinogenic effects, which counts because of their structure to the substituted phenethylamines. The effect is attributed, inter alia, on the properties of the bromo- dragonflys a potent agonist at the serotonin receptor 5-HT2A. Bromo - Dragonfly is a derivative of the DOB.

History

Bromo - Dragonfly was developed in 1998 by Matthew Parker at Purdue University. The name comes from the English ( dragonfly, dragonfly dt ) and describes the appearance of the sub- structure of the aromatics with the furan rings.

Pharmacological properties

Pharmacodynamics

Bromo - Dragonfly has a stereocenter, where R -(-) -Bromo- Dragonfly is the pharmacologically active stereoisomer. It binds with high affinity to the 5-HT2A/2B/2C-Serotoninrezeptoren with a Ki value of 0.31 nM in the 5-HT2A receptor, and 0.11 nM at the 5-HT2C receptor. For the (S )-isomer, Ki values ​​of 0.68 nM for the 5-HT2A receptor, and 0.25 nM for the 5- HT2C receptor are indicated.

Effect

Due to its high affinity at the 5 -HT2A receptor, the effect with that of LSD or DOB is similar, but the duration of action is significantly increased up to 96 hrs. Overdoses resulting in death have been described.

Legal status

• Germany